Sufficient-dose Brentuximab vedotin improves prognosis in patients with classic Hodgkin lymphoma: a single-center real-world study in China

1

This study compared the efficacy and safety of ABVD and A-AVD regimens in 243 Chinese patients with classic Hodgkin lymphoma.
2

The A-AVD group had a higher proportion of elderly patients (≥60 years) compared to the ABVD group (25.5% vs. 9.4%).
3

Two-year progression-free survival rates were 71.1% for ABVD and 76.7% for A-AVD, with no significant differences in overall survival.
4

A sufficient dose of brentuximab vedotin (≥1.15 mg/kg) significantly improved progression-free survival in advanced-stage patients.
5

The A-AVD regimen was associated with higher rates of peripheral neuropathy, while ABVD showed a trend toward increased pulmonary toxicity.

Frontiers In Oncology

by Zhangyuting He, Huiying Zhu, Chong Wei, Danqing Zhao, Jing Ruan, Wei Zhang, Daobin Zhou, Yan Zhang
July 6, 2026

1